{"id":4454,"date":"2026-06-15T10:00:49","date_gmt":"2026-06-15T08:00:49","guid":{"rendered":"https:\/\/www.fondazionebonadonna.eu\/?p=4454"},"modified":"2026-06-11T11:50:31","modified_gmt":"2026-06-11T09:50:31","slug":"efficacy-of-an-ultra-low-dose-of-immunotherapy-in-relapsed-refrfactory-solid-tumors","status":"publish","type":"post","link":"https:\/\/www.fondazionebonadonna.eu\/en\/efficacy-of-an-ultra-low-dose-of-immunotherapy-in-relapsed-refrfactory-solid-tumors\/","title":{"rendered":"Efficacy of an ultra-low dose of immunotherapy in relapsed refrfactory solid tumors"},"content":{"rendered":"<div class=\"wpb-content-wrapper\"><p>[vc_row][vc_column][vc_custom_heading text=&#8221;An ultra-low dose of nivolumab significantly improves overall survival in heavily pretreated advanced solid tumors, with fewer toxicities and better quality of life &#8221; font_container=&#8221;tag:h3|text_align:left&#8221; use_theme_fonts=&#8221;yes&#8221;][\/vc_column][\/vc_row][vc_row][vc_column width=&#8221;1\/2&#8243;][vc_column_text]Data from the the DELII phase III superiority trial, <a href=\"https:\/\/ascopubs.org\/doi\/10.1200\/JCO-25-01546\" target=\"_blank\" rel=\"noopener\">recently published on the Journal of Clinical Oncology<\/a>, shows that an ultra-low dose of the immune checkpoint inhibitor nivolumab retains clinical efficacy in patients with relapsed refractory solid tumors, with fewer toxicity and better quality of life, thus potentially improving affordability of immunotherapy.<\/p>\n<p>The study is an open-label phase III superiority trial where 500 patients with advanced, heavily pretreated solid tumors (of which 52% head and neck cancers, 36% lung cancers) were randomized to receive an ultra-low dose of nivolumab (20 mg every 2 weeks, i.e. 8% of the conventional dose) or chemotherapy. Results showed that median overall survival was 5.88 months with ultra-low dose nivolumab versus 4.7 months with chemotherapy; one year overall survival were 27.3% and 16.9% respectively. Median progression-free survival and objective response rates did not significantly differ between the two treatment groups, but duration of response reached 8.28 months with ultra-low dose nivolumab versus 4.93 months with chemotherapy. Safety with ultra-low dose nivolumab was substantially improved and quality of life was significantly better compared with chemotherapy. As authors point out, \u00abonly a very small proportion of eligible patients in many low- and middle-income countries are currently able to receive checkpoint inhibitors because of cost limitations. These findings support re-evaluation of immune checkpoint inhibitor dosing strategies and may enhance global access\u00bb, they conclude.[\/vc_column_text][\/vc_column][vc_column width=&#8221;1\/2&#8243;][vc_single_image image=&#8221;2257&#8243; img_size=&#8221;large&#8221;][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>[vc_row][vc_column][vc_custom_heading text=&#8221;An ultra-low dose of nivolumab significantly improves overall survival in heavily pretreated advanced solid tumors, with fewer toxicities and better quality of life &#8221; font_container=&#8221;tag:h3|text_align:left&#8221;<span class=\"excerpt-hellip\"> [\u2026]<\/span><\/p>\n","protected":false},"author":2,"featured_media":2257,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[39,21],"tags":[],"class_list":["post-4454","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-events","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Efficacy of an ultra-low dose of immunotherapy in relapsed refrfactory solid tumors - Fondazione Gianni Bonadonna<\/title>\n<meta name=\"description\" content=\"An ultra-low dose of nivolumab significantly improves overall survival in heavily pretreated advanced solid tumors, with fewer toxicities and better quality of life\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.fondazionebonadonna.eu\/en\/efficacy-of-an-ultra-low-dose-of-immunotherapy-in-relapsed-refrfactory-solid-tumors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Efficacy of an ultra-low dose of immunotherapy in relapsed refrfactory solid tumors - Fondazione Gianni Bonadonna\" \/>\n<meta property=\"og:description\" content=\"An ultra-low dose of nivolumab significantly improves overall survival in heavily pretreated advanced solid tumors, with fewer toxicities and better quality of life\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.fondazionebonadonna.eu\/en\/efficacy-of-an-ultra-low-dose-of-immunotherapy-in-relapsed-refrfactory-solid-tumors\/\" \/>\n<meta property=\"og:site_name\" content=\"Fondazione Gianni Bonadonna\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-15T08:00:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2022\/11\/iStock-1167361072.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2500\" \/>\n\t<meta property=\"og:image:height\" content=\"1500\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fondazione Gianni Bonadonna\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fondazione Gianni Bonadonna\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/efficacy-of-an-ultra-low-dose-of-immunotherapy-in-relapsed-refrfactory-solid-tumors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/efficacy-of-an-ultra-low-dose-of-immunotherapy-in-relapsed-refrfactory-solid-tumors\\\/\"},\"author\":{\"name\":\"Fondazione Gianni Bonadonna\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/#\\\/schema\\\/person\\\/ad83ff3574293b8bca712a59db515146\"},\"headline\":\"Efficacy of an ultra-low dose of immunotherapy in relapsed refrfactory solid tumors\",\"datePublished\":\"2026-06-15T08:00:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/efficacy-of-an-ultra-low-dose-of-immunotherapy-in-relapsed-refrfactory-solid-tumors\\\/\"},\"wordCount\":299,\"image\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/efficacy-of-an-ultra-low-dose-of-immunotherapy-in-relapsed-refrfactory-solid-tumors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/wp-content\\\/uploads\\\/2022\\\/11\\\/iStock-1167361072.jpg\",\"articleSection\":[\"Events\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/efficacy-of-an-ultra-low-dose-of-immunotherapy-in-relapsed-refrfactory-solid-tumors\\\/\",\"url\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/efficacy-of-an-ultra-low-dose-of-immunotherapy-in-relapsed-refrfactory-solid-tumors\\\/\",\"name\":\"Efficacy of an ultra-low dose of immunotherapy in relapsed refrfactory solid tumors - Fondazione Gianni Bonadonna\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/efficacy-of-an-ultra-low-dose-of-immunotherapy-in-relapsed-refrfactory-solid-tumors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/efficacy-of-an-ultra-low-dose-of-immunotherapy-in-relapsed-refrfactory-solid-tumors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/wp-content\\\/uploads\\\/2022\\\/11\\\/iStock-1167361072.jpg\",\"datePublished\":\"2026-06-15T08:00:49+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/#\\\/schema\\\/person\\\/ad83ff3574293b8bca712a59db515146\"},\"description\":\"An ultra-low dose of nivolumab significantly improves overall survival in heavily pretreated advanced solid tumors, with fewer toxicities and better quality of life\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/efficacy-of-an-ultra-low-dose-of-immunotherapy-in-relapsed-refrfactory-solid-tumors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/efficacy-of-an-ultra-low-dose-of-immunotherapy-in-relapsed-refrfactory-solid-tumors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/efficacy-of-an-ultra-low-dose-of-immunotherapy-in-relapsed-refrfactory-solid-tumors\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/wp-content\\\/uploads\\\/2022\\\/11\\\/iStock-1167361072.jpg\",\"contentUrl\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/wp-content\\\/uploads\\\/2022\\\/11\\\/iStock-1167361072.jpg\",\"width\":2500,\"height\":1500},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/efficacy-of-an-ultra-low-dose-of-immunotherapy-in-relapsed-refrfactory-solid-tumors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Efficacy of an ultra-low dose of immunotherapy in relapsed refrfactory solid tumors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/#website\",\"url\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/\",\"name\":\"Fondazione Gianni Bonadonna\",\"description\":\"Fondazione Gianni Bonadonna\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/#\\\/schema\\\/person\\\/ad83ff3574293b8bca712a59db515146\",\"name\":\"Fondazione Gianni Bonadonna\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g\",\"caption\":\"Fondazione Gianni Bonadonna\"},\"url\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/author\\\/fgb\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Efficacy of an ultra-low dose of immunotherapy in relapsed refrfactory solid tumors - Fondazione Gianni Bonadonna","description":"An ultra-low dose of nivolumab significantly improves overall survival in heavily pretreated advanced solid tumors, with fewer toxicities and better quality of life","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.fondazionebonadonna.eu\/en\/efficacy-of-an-ultra-low-dose-of-immunotherapy-in-relapsed-refrfactory-solid-tumors\/","og_locale":"en_US","og_type":"article","og_title":"Efficacy of an ultra-low dose of immunotherapy in relapsed refrfactory solid tumors - Fondazione Gianni Bonadonna","og_description":"An ultra-low dose of nivolumab significantly improves overall survival in heavily pretreated advanced solid tumors, with fewer toxicities and better quality of life","og_url":"https:\/\/www.fondazionebonadonna.eu\/en\/efficacy-of-an-ultra-low-dose-of-immunotherapy-in-relapsed-refrfactory-solid-tumors\/","og_site_name":"Fondazione Gianni Bonadonna","article_published_time":"2026-06-15T08:00:49+00:00","og_image":[{"width":2500,"height":1500,"url":"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2022\/11\/iStock-1167361072.jpg","type":"image\/jpeg"}],"author":"Fondazione Gianni Bonadonna","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fondazione Gianni Bonadonna","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.fondazionebonadonna.eu\/en\/efficacy-of-an-ultra-low-dose-of-immunotherapy-in-relapsed-refrfactory-solid-tumors\/#article","isPartOf":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/efficacy-of-an-ultra-low-dose-of-immunotherapy-in-relapsed-refrfactory-solid-tumors\/"},"author":{"name":"Fondazione Gianni Bonadonna","@id":"https:\/\/www.fondazionebonadonna.eu\/#\/schema\/person\/ad83ff3574293b8bca712a59db515146"},"headline":"Efficacy of an ultra-low dose of immunotherapy in relapsed refrfactory solid tumors","datePublished":"2026-06-15T08:00:49+00:00","mainEntityOfPage":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/efficacy-of-an-ultra-low-dose-of-immunotherapy-in-relapsed-refrfactory-solid-tumors\/"},"wordCount":299,"image":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/efficacy-of-an-ultra-low-dose-of-immunotherapy-in-relapsed-refrfactory-solid-tumors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2022\/11\/iStock-1167361072.jpg","articleSection":["Events"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.fondazionebonadonna.eu\/en\/efficacy-of-an-ultra-low-dose-of-immunotherapy-in-relapsed-refrfactory-solid-tumors\/","url":"https:\/\/www.fondazionebonadonna.eu\/en\/efficacy-of-an-ultra-low-dose-of-immunotherapy-in-relapsed-refrfactory-solid-tumors\/","name":"Efficacy of an ultra-low dose of immunotherapy in relapsed refrfactory solid tumors - Fondazione Gianni Bonadonna","isPartOf":{"@id":"https:\/\/www.fondazionebonadonna.eu\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/efficacy-of-an-ultra-low-dose-of-immunotherapy-in-relapsed-refrfactory-solid-tumors\/#primaryimage"},"image":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/efficacy-of-an-ultra-low-dose-of-immunotherapy-in-relapsed-refrfactory-solid-tumors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2022\/11\/iStock-1167361072.jpg","datePublished":"2026-06-15T08:00:49+00:00","author":{"@id":"https:\/\/www.fondazionebonadonna.eu\/#\/schema\/person\/ad83ff3574293b8bca712a59db515146"},"description":"An ultra-low dose of nivolumab significantly improves overall survival in heavily pretreated advanced solid tumors, with fewer toxicities and better quality of life","breadcrumb":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/efficacy-of-an-ultra-low-dose-of-immunotherapy-in-relapsed-refrfactory-solid-tumors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.fondazionebonadonna.eu\/en\/efficacy-of-an-ultra-low-dose-of-immunotherapy-in-relapsed-refrfactory-solid-tumors\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fondazionebonadonna.eu\/en\/efficacy-of-an-ultra-low-dose-of-immunotherapy-in-relapsed-refrfactory-solid-tumors\/#primaryimage","url":"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2022\/11\/iStock-1167361072.jpg","contentUrl":"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2022\/11\/iStock-1167361072.jpg","width":2500,"height":1500},{"@type":"BreadcrumbList","@id":"https:\/\/www.fondazionebonadonna.eu\/en\/efficacy-of-an-ultra-low-dose-of-immunotherapy-in-relapsed-refrfactory-solid-tumors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.fondazionebonadonna.eu\/en\/"},{"@type":"ListItem","position":2,"name":"Efficacy of an ultra-low dose of immunotherapy in relapsed refrfactory solid tumors"}]},{"@type":"WebSite","@id":"https:\/\/www.fondazionebonadonna.eu\/#website","url":"https:\/\/www.fondazionebonadonna.eu\/","name":"Fondazione Gianni Bonadonna","description":"Fondazione Gianni Bonadonna","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.fondazionebonadonna.eu\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.fondazionebonadonna.eu\/#\/schema\/person\/ad83ff3574293b8bca712a59db515146","name":"Fondazione Gianni Bonadonna","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g","caption":"Fondazione Gianni Bonadonna"},"url":"https:\/\/www.fondazionebonadonna.eu\/en\/author\/fgb\/"}]}},"_links":{"self":[{"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/posts\/4454","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/comments?post=4454"}],"version-history":[{"count":3,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/posts\/4454\/revisions"}],"predecessor-version":[{"id":4458,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/posts\/4454\/revisions\/4458"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/media\/2257"}],"wp:attachment":[{"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/media?parent=4454"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/categories?post=4454"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/tags?post=4454"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}